About Hospital Sirio Libanes; Centro de Oncologia
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Hoffmann-La Roche
6
Clinical Trials at Hospital Sirio Libanes; Centro de Oncologia
During the past decade, Hospital Sirio Libanes; Centro de Oncologia conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 6 clinical trials were completed, i.e. on
average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 3 clinical trials were completed. i.e. 0%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
A Study to Compare Subcutaneous Versus Intravenous MabThera (Rituximab) in Combination With Chemotherapy in Patients With Chronic Lymphocytic Leukemia
2011-04-18
2017-11-17
Completed
240
A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer
2012-06-01
2019-09-20
Completed
1,436
A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment
2012-11-27
2020-07-31
Completed
2,185
A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer
2013-06-10
2019-12-31
Completed
780
A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia
2013-11-04
2018-10-08
Completed
979
A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer
2014-01-31
2021-06-04
Completed
1,846
Clinical Trials Sponsors and Collaborators
Clinical Trials Conditions at Hospital Sirio Libanes; Centro de Oncologia
According to Clinical.Site data, the most researched conditions in "Hospital Sirio Libanes; Centro de Oncologia" are
"Breast Cancer" (2 trials), "Breast Neoplasms" (1 trials), "Chronic Lymphocytic Leukemia" (1 trials), "Gastric Cancer" (1 trials) and "Lymphocytic Leukemia, Chronic" (1 trials). Many other conditions were trialed in "Hospital Sirio Libanes; Centro de Oncologia" in a lesser frequency.
Clinical Trials Intervention Types at Hospital Sirio Libanes; Centro de Oncologia
Most popular intervention types in "Hospital Sirio Libanes; Centro de Oncologia" are "Drug" (6 trials). Other intervention types were less common.
The name of intervention was led by "Cyclophosphamide" (3 trials), "Pertuzumab" (3 trials), "Trastuzumab" (3 trials), "5-Fluorouracil" (2 trials) and "Docetaxel" (2 trials). Other intervention names were less common.
Clinical Trials Genders at Hospital Sirio Libanes; Centro de Oncologia
The vast majority of trials in "Hospital Sirio Libanes; Centro de Oncologia" are
6 trials for "All" genders.
Clinical Trials Status at Hospital Sirio Libanes; Centro de Oncologia
Currently, there are NaN active trials in "Hospital Sirio Libanes; Centro de Oncologia".
undefined are not yet recruiting,
undefined are recruiting,
undefined are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 6 completed trials in Hospital Sirio Libanes; Centro de Oncologia,
undefined suspended trials,
and undefined terminated clinical trials to date.
Out of the total trials that were conducted in Hospital Sirio Libanes; Centro de Oncologia, 1 "Phase 1"
clinical trials were conducted, 0 "Phase 2" clinical
trials and 5 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".